Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

This trial is testing whether adding venetoclax (a drug that helps cancer cells die) to standard intensive chemotherapy improves outcomes for patients with acute myeloid leukemia (AML) — a fast-growing blood cancer. **You may be eligible if...** - You have been diagnosed with AML or high-risk myelodysplastic syndrome (MDS, a bone marrow disorder with at least 10% abnormal cells) - You are either newly diagnosed OR your AML has come back or has not responded to prior treatment - Your general health is good enough to receive intensive chemotherapy (ECOG score of 0, 1, or 2) - If you are over 65, your doctor and the study team have determined you are healthy enough for intensive treatment **You may NOT be eligible if...** - Your general health is too poor for intensive chemotherapy - You have uncontrolled infections or other conditions making treatment unsafe Talk to your doctor to see if this trial is right for you.